We recently reported the clinical significance of therapeutic monitoring of anti-PD-1 antibody by 18F-FDG PET9 and the close relationship between 18F-FDG uptake and PD-L1 expression within tumor cells by immunohistochemistry10–12. The gene discussed is CD274; the disease is neoplasm.